|
Australian Patent Number 2003221575 issued for “TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND USES THEREOF” January 17, 2011 – New York - Protagenic Therapeutics, Inc., a privately held biotechnology company focused on developing and commercializing novel, naturally occurring human brain peptide hormones for the treatment of mood and anxiety disorders, announced today that the Australian Patent Number 2003221575 was issued by the Australian Government on September 23, 2010. TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND USES THEREOF was invented by Lovejoy, David; Chewpoy, Bradley R.; Barsyte, Dalia; and Rotzinger, Susan. The patent was issued in the name of the inventors and it has a potential Term of 20 years. It should be noted that the Protagenic Therapeutics., Inc. has obtained worldwide exclusive rights to the peptide technology that was developed at the University of Toronto, Ontario.
Protagenic Therapeutics has created a proprietary portfolio of novel neuropeptides, which are in various stages of development and preclinical evaluation for the treatment of neuropsychiatric and other disorders. Novel peptide targets may also have applications in the areas of neuroregeneration, spinal cord injuries and cancer. About the Lead Product PT00114 is a peptide formulation currently in preclinical development for the treatment of anxiety and depression disorders. The active peptide hormone appears to selectively target cells under physiological stress, and does not appear to have an impact on normal, healthy cells. This suggests that as a treatment, PT00114 has the potential to restore normality to the patient without affecting cognitive function or causing other unwanted side effects. For further information please contact us at: January 17, 2011 Australian Patent Number 2003221575 issued for “TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND USES THEREOF”. PDF
|
 |
